1. Prospective validation of the International Warfarin Pharmacogenetics Consortium algorithm in high-risk elderly people (VIALE study).
- Author
-
Filippelli A, Signoriello S, Bancone C, Corbi G, Manzo V, Iesu S, Politi C, Gigantino A, De Donato MT, Masiello P, Simeon V, Della Corte A, Cellurale M, Conti V, Frigino M, Ciarambino T, Marracino M, Carpenito L, Ferrara N, De Feo M, and Gallo C
- Subjects
- Aged, Aged, 80 and over, Anticoagulants adverse effects, Atrial Fibrillation drug therapy, Atrial Fibrillation genetics, Cohort Studies, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Heart Valve Diseases drug therapy, Heart Valve Diseases genetics, Humans, Male, Prospective Studies, Risk Factors, Warfarin adverse effects, Algorithms, Anticoagulants administration & dosage, Internationality, Pharmacogenetics standards, Warfarin administration & dosage
- Abstract
We assessed the predictive accuracy of the Warfarin Pharmacogenetics Consortium (IWPC) algorithm in a prospective cohort of 376 high-risk elderly patients (≥65 years) who required new treatment with warfarin for either medical (non valvular atrial fibrillation) or surgical conditions (heart valve replacement), had ≥1 comorbid conditions, and regularly used ≥2 other drugs. Follow-up visits were performed according to clinical practice and lasted for a maximum of 1 year. Two hundred and eighty-three (75%) patients achieved a stable maintenance dose. Warfarin maintenance doses were low on average (median 20.3 mg/week, interquartile range, 14.1-27.7 mg/week) and were substantially overestimated by the IWPC algorithm. Overall the percentage of patients whose predicted dose of warfarin was within 20% of the actual stable dose was equal to 37.5%, (95% CI 32.0-43.3%). IWPC algorithm explained only 31% of the actual warfarin dose variability. Modifications of the IWPC algorithm are needed in high-risk elderly people.
- Published
- 2020
- Full Text
- View/download PDF